BioMerieux Invests $5M in Knome; Licenses Firm's Analysis Platform for Sequencing-Based IVDs

The collaboration is part of BioMérieux's five-year strategy to incorporate next-gen sequencing into a platform for in vitro diagnostics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories